Although oral antidiabetic medications initially may be effective for controlling hyperglycemia, these agents often fail to maintain adequate glycemic control as the disease progresses, and insulin eventually is required in most patients. This review explores strategies for identifying patients with type 2 diabetes who are failing to maintain glycemic control...
To determine the prevalence of, and patient characteristics associated with, Antiplatelet therapy in a cohort of primary care patients with Type 1 or Type 2 diabetes. Subjects participating in a randomized trial of a decision support system were interviewed at home and medication usage verified by a research assistant. Despite...
The problem of poor compliance/adherence to prescribed treatments is very complex. Health professionals are rarely being asked how they handle the patient's poor therapy compliance/adherence. This study examines explicitly the physicians' expectations of their diabetes patients' compliance/adherence. The objectives of the study is to elicit problems physicians encounter with type...
Experimental evidence supports the hypothesis that Persistent Organochlorine Pollutants POPs may cause type 2 diabetes mellitus, whereas there is no fully convincing epidemiological evidence for such an association. In Sweden the most important source of POP exposure is fatty fish. This paper assesses the association between serum levels of POPs...
The paper informs that investment into researching and developing new products in the UK is now running at around ·3.2 billion a year and each new medicine takes an average of ten to twelve years to develop before it is authorized for use by doctors, with no guarantee of commercial...
This division designs and manufactures a variety of Type 2 medical devices for the consumer market. PACE (Product And Cycle-time Excellence) implementation focused on improved product planning and reducing time-to-market across an organization with worldwide marketing, development in the eastern US, and plants in the country's Midwest. PACE was implemented...
R.J Steffens submits: The American Diabetes Association's 68th Scientific Sessions kicked off in San Francisco on June 6th and ends June 10th. Large pharma dominates the exhibition and use the venue to present their latest study results in an effort to orientate health care professionals on the products they may...
You can't fault GlaxoSmithKline for temerity. The U.K. drugmaker's unexpectedly large $720 million bid for Sirtris Pharmaceuticals represents a gutsy bet that the Massachusetts biotech really has a handle on a class of drugs that slow aging. Not that anyone at either company is eager to describe their work that...
